;
Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Figure: Money Raised in 2014

    Safety equals cash Money Raised in 2014 Last week, the biotech industry raised $5,222 million, bringing to $49.4 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 11/17/2014
  • Table: EPS watch

    Safety equals cash EPS watch At least five companies reported earnings last week. Company 3Q14 EPS est 3Q14 EPS actual Outcome Growth from 3Q13 11/14 cls Wk chg % chg Mcap chg 11/14 Mcap Evotec AG (Xetra:…

    Published on 11/17/2014
  • Impatient clinical development

    How Impatient hopes to direct charitable donations to specific clinical trials

    Ebb & Flow Impatient clinical development While healthcare and disease-related charities raise enormous sums of money, it isn't always clear how much goes to research. When it does, the funds typically are used for …

    Published on 11/17/2014
  • MedImmune gets Definiens' digits

    Time was ripe for AstraZeneca to bring Definiens technology in house

    Ebb & Flow MedImmune gets Definiens' digits After about a decade of using technology from Definiens AG, MedImmune LLC is pulling the trigger and buying the biotech outright. The unit of AstraZeneca plc (LSE:AZN; …

    Published on 11/17/2014
  • Safety equals cash

    Why investors put $33.1 million into dermatology play Ziarco

    Ebb & Flow Safety equals cash Figure: Money Raised in 2014 Table: EPS watch Ziarco Group Ltd.'s combination of preclinical safety data and a better understanding of the mechanism of its lead asset led new …

    Published on 11/17/2014
  • Figure: Converting the middle

    Convert resurgence Converting the middle Of the 26 biotechs raising $10 million or more in convertible debt so far in 2014, only two were over $5 billion in market cap at the start of the year. Mid-caps between $500…

    Published on 11/10/2014
  • Figure: Money Raised in 2014

    Convert resurgence Money Raised in 2014 Last week, the biotech industry raised $395 million, bringing to $44.2 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 11/10/2014
  • Table: Earnings on deck

    Convert resurgence Earnings on deck At least six companies are slated to report earnings this week. PDL BioPharma Inc. (NASDAQ:PDLI) is expected to report double-digit earnings growth on a 70% increase in revenues …

    Published on 11/10/2014
  • Table: EPS watch

    Convert resurgence EPS watch At least 18 companies reported earnings last week. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) fell 36%, losing $3.3 billion in market cap last week, after reporting that current wholesale …

    Published on 11/10/2014
  • Imago-in' places

    Imago reunites FerroKin vets to target gene expression in blood disorders

    Ebb & Flow Imago-in' places The team at Imago BioSciences Inc. raised a $26.5 million series A round geared to helping them repeat their performance at hematology play FerroKin BioSciences Inc., this time with …

    Published on 11/10/2014
  • Bayer's ear to the ground

    Why Bayer is investing up to $25M in Versant's fifth fund

    Ebb & Flow Bayer's ear to the ground The Bayer HealthCare unit of Bayer AG (Xetra:BAYN) is expanding its relationship with Versant Ventures by becoming an LP in the VC firm's new fund. Christopher Haskell, head of …

    Published on 11/10/2014
  • Convert resurgence

    Why biotech convertible debt deals are at highest levels since 2006

    Ebb & Flow Convert resurgence Figure: Money Raised in 2014 Figure: Converting the middle Table: Earnings on deck Table: EPS watch Biotechs have raised $5.6 billion through convertible debt financings so far this…

    Published on 11/10/2014
  • Fresh fund, same plan

    Advent sticking with investment strategy for L145.5M second life sciences fund

    Ebb & Flow Fresh fund, same plan Advent Venture Partners plans to stick with its long-standing investment strategy for its second dedicated life sciences fund, Advent Life Sciences Fund II, which the firm closed …

    Published on 11/3/2014
  • Figure: Money Raised in 2014

    Shooting F-stars Money Raised in 2014 Last week, the biotech industry raised $630 million, bringing to $43.8 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14.4 …

    Published on 11/3/2014
  • Table: Earnings on deck

    Shooting F-stars Earnings on deck At least 17 biotechs and pharmas are slated to report earnings this week. Two large-cap biotechs - Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Salix Pharmaceuticals Ltd. (…

    Published on 11/3/2014
  • Table: EPS watch

    Shooting F-stars EPS watch At least 34 biotechs and pharmas reported earnings last week. Amgen Inc. (NASDAQ:AMGN) tacked on $11.4 billion in market cap value after beating the Street's EPS and revenue estimates and …

    Published on 11/3/2014
  • Shooting F-stars

    How BMS deal validates F-star's asset-centric spinout strategy

    Ebb & Flow Shooting F-stars Figure: Money Raised in 2014 Table: Earnings on deck Table: EPS watch F-star Alpha Ltd.'s deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent …

    Published on 11/3/2014
  • Enhancing super-enhancers

    Syros to use $53M to advance cancer program, expand super-enhancer platform

    Ebb & Flow Enhancing super-enhancers With a new injection of cash, Syros Pharmaceuticals Inc. plans to move its lead cancer program into the clinic, continue to build out its super-enhancer platform technology and …

    Published on 11/3/2014
  • Metallic strategy

    Why Viamet chose to stay private and spin out cancer assets

    Ebb & Flow Metallic strategy Viamet Pharmaceuticals Inc.'s decision to do a $60 million series D round one day after withdrawing its planned $75 million IPO late last month can be explained by a "choppy" IPO market …

    Published on 11/3/2014
  • Not slowing down

    Biogen Idec says $100M cut doesn't mean less BD

    Ebb & Flow Not slowing down The $100 million reduction by Biogen Idec Inc. (NASDAQ:BIIB) of guidance for business development spending for the remainder of the year does not reflect a change in strategy or appetite,…

    Published on 10/27/2014
  • Tecfidera tremors

    Buysiders say jittery investors overreacted on Biogen's Tecfidera sales, PML case

    Ebb & Flow Tecfidera tremors Buysiders said investors overreacted when they shaved as much as $8.5 billion off the market cap of Biogen Idec Inc. (NASDAQ:BIIB) on Wednesday on 3Q14 sales of Tecfidera dimethyl …

    Published on 10/27/2014
  • Figure: Money Raised in 2014

    Waiting for better times Money Raised in 2014 Last week, the biotech industry raised $431 million, bringing to $43.1 billion the total raised year-to-date. In 2013, a total of $37.2 billion was raised, including $14…

    Published on 10/27/2014
  • Table: Earnings on deck

    Waiting for better times Earnings on deck At least 31 biotechs and pharmas are slated to report earnings this week. Investors will be closely watching Amgen Inc. (NASDAQ:AMGN) when it reports earnings on Monday for …

    Published on 10/27/2014
  • Table: EPS watch

    Waiting for better times EPS watch At least 18 biotechs and pharmas reported earnings last week. Four large-cap biotechs - Actelion Ltd. (SIX:ATLN), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), BioMarin …

    Published on 10/27/2014
  • Figure: NewLink on the move

    Playing NewLink NewLink on the move Shares of NewLink Genetics Corp. (NASDAQ:NLNK) since April 30.

    Published on 10/27/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993